Cingulate (CING) News
NASDAQ: CINGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CING news summary
We found 3 recent headlines mentioning Cingulate (CING): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire. CING is making an outsized move today, down 14.26% at $4.51, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cingulate headlines
- Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology PlatformNew Patent Strengthens Cingulate’s Intellectual Property Portfolio While Company Maintains Focus on Advancing Lead ADHD Candidate CTx-1301 New Patent Strengthens Cingulate’s Intellectual Property…GlobeNewswire
- Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA ResubmissionManufacturing Work Addressing FDA CMC Information Requests Substantially CompletedGlobeNewswire
- Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane KingKANSAS CITY, Kan., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to…GlobeNewswire